Skip to main content

$0.043 0.002 (4.88%)

High

$0.05

Low

$0.04

Trades

61

Turnover

$61,445

Volume

1,415,719
30 June 2023 at 4:10pm
Register to track NOX and receive email alerts.
Subject
NOX Ann: Change of Director's Interest Notice - FB

NOX Ann: Change of Director's Interest Notice - FB

NOX Ann: Change of Director's Interest Notice - BP

NOX Ann: Change of Director's Interest Notice - PM

NOX Ann: Details of Company Address

NOX Ann: IONIC Trial Abstract Published at ASCO

NOX Ann: Study results show new Sofra drug reduces inflammation

NOX Ann: Innovative Sofra research presented at European event

NOX Ann: Change of Director's Interest Notice - FB

NOX Ann: Upcoming Expiry of Listed Options (ASX Code NOXO)

NOX Ann: Change of Director's Interest Notice - FB

NOX Ann: March 2023 Quarterly Activities Report and Appendix 4C

NOX Ann: Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs

NOX Ann: Noxopharm Announces Novel mRNA Vaccine Enhancer

NOX Ann: Appendix 4D and Half Year 2023 Financial Report

NOX Ann: Noxopharm to Present Sofra Study at LUPUS 2023 Conference

NOX Ann: December 2022 Quarterly Activities Report and Appendix 4C

NOX Ann: DARRT-2 Trial Efficacy Phase to Commence

NOX Ann: NOX Pipeline Boosted by $1.5M Grant to Hudson Institute

NOX Ann: Change of Director's Interest Notice - FB

NOX Ann: Notification of cessation of securities - NOX

NOX Ann: Federal Innovation Connections Grant Awarded

NOX Ann: IONIC Trial Progresses as Veyonda Passes Safety Milestone

NOX Ann: Notification of cessation of securities - NOX

NOX Ann: Constitution

NOX Ann: Results of Meeting

NOX Ann: Noxopharm 2022 AGM Corporate Presentation

NOX Ann: Noxopharm AGM 2022 Chair's Address

NOX Ann: CEP-2 Safety Milestone Shows Veyonda Progress

NOX Ann: Noxopharm Enhances Cash Position via R&D Rebate

NOX Ann: Change in substantial holding

NOX Ann: September 2022 Quarterly Activities Report and Appendix 4C

NOX Ann: 2022 AGM Notice of Meeting and Proxy

NOX Ann: 2022 AGM Letter to Shareholders and Proxy

NOX Ann: Unlisted Options Expiring on 21 November 2022

NOX Ann: Noxopharm 2022 Annual Report

NOX Ann: Final Director's Interest Notice - GK

NOX Ann: Resignation of Dr Graham Kelly as Non-Executive Director

NOX Ann: Novel Dual-cell Therapy Results in Pancreatic Cancer

NOX Ann: Response to ASX Price Query (Correction to ASX Ticker)

NOX Ann: Response to ASX Price Query

NOX Ann: Appendix 4E and Audited Financial Statements

NOX Ann: Appendix 4G and Corporate Governance Statement

NOX Ann: Noxopharm & UNSW Pancreatic Cancer Research at US Conference

NOX Ann: CEP-2 Trial Passes Safety Milestone

NOX Ann: DARRT-2 Trial Safety Milestone and European Site Activated

NOX Ann: June 2022 Quarterly Activities Report and Appendix 4C

NOX Ann: Mayo Clinic and Washington Uni Join Noxopharm Sarcoma Trial

NOX Ann: $1.45M Grant to Hudson Institute for Noxopharm Collaboration

NOX Ann: HIMR Collaboration Secures mRNA Vic Acceleration Fund Grant

Register to track NOX and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX